ArticleInternational journal of clinical oncology2011
Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma.
Article in International journal of clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Unveiling the potential of galectin-3 as a diagnostic biomarker for pancreatic cancer: a review.Annals of medicine and surgery (2012) · 2023Article
- Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- The role of galectins‑1, 3, 7, 8 and 9 as potential diagnostic and therapeutic markers in ovarian cancer (Review).Molecular medicine reports · 2022Article
- Review
- Galectins and Ovarian Cancer.Cancers · 2020Review
- Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids.Cancer medicine · 2019Article
- The Role of Galectins in Tumor Progression, Treatment and Prognosis of Gynecological Cancers.Journal of Cancer · 2018Review
- Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer.Cancer management and research · 2018Article
- Intranuclear accumulation of galectin-3 is an independent prognostic factor for patients with distal cholangiocarcinoma.Oncology letters · 2017Article
- Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.International journal of molecular sciences · 2017Article
- Role of Galectin-3 Combined with Multi- Detector Contrast Enhanced Computed Tomography in Predicting Disease Recurrence in Patients with Ovarian CancerAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain.Oncotarget · 2016Article
- Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Expression of immune checkpoint molecules in endometrial carcinoma.Experimental and therapeutic medicine · 2015Article
- Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia.Journal of pathology and translational medicine · 2015Review
- Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.Cancer immunology, immunotherapy : CII · 2014Article
- Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.Cell death & disease · 2014Article
- Serum galectin-3 levels in women with PCOS.Journal of endocrinological investigation · 2014Article
- Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence.World journal of urology · 2013Article
- Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGalectin-3 (Gal-3) is a β-galactoside-binding lectin involved in regulating cell growth, angiogenesis, and tumor progression. We investigated the clinical significance of Gal-3 expression including its possible use as a prognostic marker or therapeutic target in epithelial ovarian carcinoma (EOC).
methodsGal-3 expression was evaluated by immunohistochemistry in 71 patients with 54 serous, 13 endometrioid, and 4 mucinous ovarian carcinomas. We assessed the correlation of Gal-3 expression with clinical characteristics including histology, optimal debulking, chemosensitivity, and survival. In vitro, Gal-3 was inhibited using siRNA to evaluate its role in cell growth and sensitivity to chemotherapeutic agents in ovarian carcinoma cell lines.
resultsGal-3 protein, which was mainly cytoplasmic in location, was observed in a majority (63/71, 88.7%) of the EOCs but not in normal ovarian tissues (P < 0.001). High Gal-3 expression in EOCs correlated with shorter progression-free survival (PFS) of patients (P = 0.039; 43.1 and 49.5 months, respectively). Moreover, cotreatment with Gal-3 siRNA and paclitaxel showed an enhanced cytotoxic effect compared with control siRNA in SKOV3 cells.
conclusionThese findings suggest that Gal-3 expression can be a prognostic factor for PFS and may be involved in regulating the response to paclitaxel-based chemotherapy in the treatment of EOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.